A study claims newly diagnosed patients with relapsing-remitting multiple sclerosis (RRMS) showed significant improvements when treated with delayed-release dimethyl fumarate (DMF), especially in terms of reduction in confirmed disability progression.
The report, Efficacy Of Delayed-Release Dimethyl Fumarate In Newly Diagnosed Patients With Multiple Sclerosis Using A Composite Measure Of Disability, was presented at the annual meeting of the Consortium of Multiple Sclerosis Centres in America.
The results of the Phase 3 clinical trials DEFINE and CONFIRM showed DMF had a significant effect in reducing confirmed disability progression in patients newly diagnosed with RRMS (measured using the Expanded Disability Status Scale, EDSS).
Researchers have now hypothesised that using multiple neuroperformance components could potentially enhance confirmed disability progression assessment.
The study included 221 patients under DMF therapy and 223 patients in the placebo group. The team observed DMF significantly reduced both the risk for 12-week and 24-week composite-confirmed disability progression, when compared to the placebo control group (assessed at the second year of treatment).
In conclusion, the results showed that DMF has significant benefits on a composite measure of disability progression when compared to placebo, in newly diagnosed patients with RRMS.
“These findings are consistent with previously published data suggesting the potential for greater clinical benefits in patients with RRMS who receive DMF treatment early in their disease course,” concluded the team in their presentation.
“The composite CDP [confirmed disability progression] measure proposed here may be more reliable than assessing its individual components alone, capturing clinically meaningful changes in disability progression across multiple neuro-performance components.”
Source: Multiple Sclerosis News Today, 06 June 2016, Patricia Inacio PHD